fda tirzepatide news FDA's decision creates uncertainty for patients—and leads to a lawsuit FDA approves new version of

Surg Laparosc Endosc Percutan Tech

Unlike traditional protocols that begin at 0.25 mg weekly, microdosing may begin as low as 0.05 mg

Heritable aspects of endometriosis

In the ELIXA CVOT, lixisenatide was found to be non-inferior to standard of care plus placebo in terms of risk of the composite endpoint (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina)13.4% in the lixisenatide group and 13.2% in the placebo group (hazard ratio, 1.02

Existing studies have revealed strategies employed by H

Frankly, one does not need a credential at all to offer unhelpful and shortsighted advice